NewAmsterdam Pharma Company (NasdaqGM:NAMS) 2026 Conference Transcript

Summary of NewAmsterdam Pharma Conference Call Company Overview - Company: NewAmsterdam Pharma (NasdaqGM:NAMS) - Lead Asset: Obicetrapib Key Updates and Core Points - Clinical Trials Progress: - Completed Phase 3 trials: BROOKLYN, BROADWAY, and TANDEM, demonstrating obicetrapib's efficacy as a potent oral LDL-lowering drug [4][5] - Achieved LDL lowering in the 50% range when combined with ezetimibe, comparable to injectable therapies [4] - BROADWAY data showed a 21% MACE (Major Adverse Cardiac Events) benefit in a mini outcome study with 2,500 patients over one year [5] - PREVAIL trial designed with 9,500 patients to maximize success, focusing on high baseline LDL levels [5][6] - Regulatory and Market Opportunities: - Filed for approval in Europe, with potential launch in late 2026, starting in Germany and the U.K. [10] - Projected market potential for obicetrapib is $8 billion or higher, with 40%-50% of sales expected from outside the U.S. [10] - Expected royalties from the partnership with Menarini in the low double-digit to mid-20% range, with €800 million in milestones contingent on European approvals [11] - Diabetes and Expanded Indications: - RUBENS study focuses on diabetic patients, aiming to expand the label to include those without heart disease, potentially increasing the patient population by $20 million [6][61] - The drug shows significant efficacy in diabetic patients, with a focus on improving glycemic indices [61] - Market Competition: - Acknowledgment of Merck's upcoming oral PCSK9 therapy, with expectations of launching ahead in the U.S. but with different mechanisms and benefits [33][34] - Emphasis on the unique characteristics of obicetrapib, including Lp(a) lowering and diabetes benefits, which may differentiate it in the market [34][35] - Alzheimer's Initiative: - Plans for a Phase IIb trial targeting Alzheimer's, leveraging findings related to lipid metabolism and APOE4 gene associations [70][74] - Previous studies indicated obicetrapib's potential to stabilize biomarkers related to cognitive decline, with a focus on prevention rather than treatment [77][78] Additional Important Insights - Imaging Studies: - The REMBRANDT study aims to show plaque reduction, which could influence prescriber mindsets and drive uptake of obicetrapib [62][68] - The study is expected to be one of the first to demonstrate plaque reduction with a drug, enhancing its promotional potential [63] - Market Dynamics: - The potential for treatment guidelines to evolve, possibly doubling the patient population eligible for lipid therapies [36] - The importance of achieving LDL goals and the role of obicetrapib in achieving these goals, especially in high-risk populations [36][37] - Regulatory Landscape: - Discussion on the FDA's evolving approach to MACE studies and how it may benefit obicetrapib's labeling [15][16] This summary encapsulates the key points discussed during the conference call, highlighting NewAmsterdam Pharma's strategic direction, clinical advancements, and market positioning.